{"entity":{"id":"famhp","kind":"institution","name":"Federal Agency for Medicines and Health Products (FAMHP)","aka":["FAMHP","AFMPS","FAGG","Agence fédérale des médicaments et des produits de santé","Federaal agentschap voor geneesmiddelen en gezondheidsproducten"],"tldr":"Belgium's medicines regulator. It authorises clinical trials in Belgium under the European regulation, approves compassionate use and medical need programmes that give patients a medicine before it is on the market, and monitors side effects.","summary":"The FAMHP is the competent authority for medicines and health products in Belgium; new cancer medicines are authorised centrally for the whole European Union, so its role for them lies mainly in trials, early access and safety. Its compassionate use and medical need programmes follow the Royal Decree of 25 April 2014, in force from 1 July 2014; its page lists the authorised programmes, which in November 2026 included trastuzumab deruxtecan for HER2-positive (IHC 3+) solid tumours with no satisfactory treatment options and niraparib with abiraterone for metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations. A medicine already in such a programme is one of the two routes into the national insurer's Early and Equitable Fast Access procedure. For trials it points patients to the EU clinical trials database and publishes a quarterly dashboard of initial applications decided in Belgium under the clinical trials regulation.\n\nIts announcement of its 2025 annual report, dated 19 October 2026, gives 654 staff, names Hugues Malonne as chief executive officer, and says that 2025 was marked by the case of a sperm donor carrying a TP53 gene mutation, which affected many families and led the agency to analyse how protection could be strengthened. The FAMHP's pages, which had served a bot challenge to an earlier check, answered on 17 November 2026, and what this record takes from them (the decree, the programmes, the dashboard, the staff count, the chief executive and the annual report) was read again there.","asOf":"2026-11-11","links":[{"label":"FAMHP: compassionate use and medical need programmes","url":"https://www.famhp.be/en/human_use/medicines/medicines/research_development/compassionate_use_medical_need"},{"label":"FAMHP: clinical trials for human medicines","url":"https://www.famhp.be/en/human_use/medicines/medicines/research_development/clinical_trials"},{"label":"FAMHP: 2025 annual report announcement (19 October 2026)","url":"https://www.famhp.be/en/news/ensuring_access_to_treatments_today_while_preparing_for_those_of_tomorrow"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","niraparib","abiraterone"],"companies":[],"institutions":["riziv-inami","ema"],"pathways":[],"terms":[],"trials":[],"people":["hugues-malonne"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.85,"lng":4.35,"institutionType":"government","website":"https://www.famhp.be","programs":["Clinical trial authorisation under the EU regulation","Compassionate use and medical need programmes (Royal Decree of 25 April 2014)","Pharmacovigilance","Medicine availability and shortages"]},"route":"/institutions/famhp/","neighbours":{"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/"},{"id":"riziv-inami","kind":"institution","name":"National Institute for Health and Disability Insurance (RIZIV-INAMI)","route":"/institutions/riziv-inami/"}],"person":[{"id":"hugues-malonne","kind":"person","name":"Hugues Malonne","route":"/people/hugues-malonne/"}]}}